Compounded Tirzepatide Dosage Chart & Titration Schedule
Compounded tirzepatide provides 60-75% cost savings versus brand Mounjaro/Zepbound while maintaining identical weight loss and diabetes control efficacy. Understanding the complete titration schedule, vial concentrations, volume calculations, and injection technique ensures safe, accurate dosing for this powerful dual GLP-1/GIP receptor agonist.
Understanding Tirzepatide: Mechanism and Advantages
Tirzepatide is a dual GLP-1/GIP receptor agonist—it activates two distinct appetite-regulating pathways in the brain, unlike semaglutide which activates only GLP-1 receptors. This dual mechanism produces superior weight loss: approximately 22% body weight reduction at maintenance dose versus 15-18% for semaglutide.
GLP-1 receptors regulate glucose levels, appetite, and gastric emptying. GIP receptors regulate energy metabolism and appetite. Simultaneous activation of both pathways produces synergistic appetite suppression, greater weight loss, and more robust glucose control.
Tirzepatide is FDA-approved for both type 2 diabetes treatment (brand name Mounjaro) and weight loss treatment (brand name Zepbound). The titration schedule and dosing are identical for both indications. The distinction is purely regulatory and insurance-related.
Tirzepatide causes more intense gastrointestinal side effects than semaglutide, particularly nausea and vomiting, especially during dose escalation. The extended 6-step titration schedule (20+ weeks) is specifically designed to minimize these effects by allowing gradual adjustment.
Compounded tirzepatide is prepared from pharmaceutical-grade tirzepatide powder mixed with sterile solutions by licensed pharmacy compounders. The tirzepatide molecule is chemically identical to brand Mounjaro and Zepbound, but the preparation and delivery system differ.
Complete FDA-Approved Tirzepatide Titration Schedule
The tirzepatide titration schedule consists of 6 progressive dose increases over approximately 20 weeks, allowing gradual adjustment to minimize side effects:
Weeks 1-4: Starting dose 2.5mg once weekly—Initiates GLP-1/GIP receptor activation with minimal side effects. Most patients tolerate 2.5mg without difficulty. First dose usually produces mild appetite suppression.
Weeks 5-8: Escalate to 5mg once weekly—Doubles initial dose intensity. Appetite suppression intensifies. Nausea may emerge at this dose level in some patients. Most tolerate 5mg without significant difficulty.
Weeks 9-12: Escalate to 7.5mg once weekly—Intermediate dose with substantial weight loss benefit. Many patients experience peak nausea at this escalation. Some patients need 5-6 weeks at 7.5mg to adjust before escalating further.
Weeks 13-16: Escalate to 10mg once weekly—Produces significant weight loss for most patients. Many patients achieve desired results at 10mg and remain at this dose long-term without escalating to 12.5mg or 15mg. Side effects are usually manageable at 10mg if tolerated through earlier escalations.
Weeks 17-20: Escalate to 12.5mg once weekly—Higher-dose patients progress here. Weight loss continues increasing. Not all patients reach this dose; many achieve adequate results at 10mg.
Week 21+: Maintenance dose 15mg once weekly—Maximum approved dose. Clinical trials demonstrated maximal weight loss results at 15mg. Maintenance continues at 15mg indefinitely as long as tolerated and beneficial. Some patients remain on lower doses (10mg) if earlier doses produce adequate results.
The standard interval between dose increases is 4 weeks. However, titration pace can be adjusted: some patients titrate faster (every 2-3 weeks) if tolerating doses well; others titrate slower (every 6-8 weeks) if experiencing side effects. Discuss your optimal titration pace with your prescribing provider.
Tirzepatide Dosage Chart: Complete Titration with Volume Conversions
The following comprehensive chart shows the complete tirzepatide dosing schedule with calculated injection volumes for standard compounded concentrations:
| Week | Dose (mg) | Volume @ 5mg/mL | Volume @ 10mg/mL | Volume @ 20mg/mL | Frequency |
|---|---|---|---|---|---|
| 1-4 | 2.5 | 0.5 mL | 0.25 mL | 0.125 mL | Once weekly |
| 5-8 | 5.0 | 1.0 mL | 0.5 mL | 0.25 mL | Once weekly |
| 9-12 | 7.5 | 1.5 mL | 0.75 mL | 0.375 mL | Once weekly |
| 13-16 | 10.0 | 2.0 mL | 1.0 mL | 0.5 mL | Once weekly |
| 17-20 | 12.5 | 2.5 mL | 1.25 mL | 0.625 mL | Once weekly |
| 21+ | 15.0 | 3.0 mL | 1.5 mL | 0.75 mL | Once weekly |
Understanding Vial Concentrations and Practical Selection
Compounded tirzepatide is available in multiple concentrations. Understanding concentrations and their practical implications helps select optimal formulation:
5mg/mL concentration is most practical for compounded tirzepatide because: (1) All doses produce measurable volumes (0.5-3.0mL). (2) Standard insulin syringes accurately measure these volumes. (3) Volume consistency throughout titration simplifies adherence. (4) Less risk of measurement errors. Most patients prefer 5mg/mL for these reasons.
10mg/mL concentration is intermediate and suitable for patients comfortable with smaller volumes (0.25-1.5mL). This concentration reduces injection volume by half compared to 5mg/mL, which some patients prefer. However, starting dose volumes (0.25mL) approach measurement accuracy limits of standard insulin syringes.
20mg/mL concentration is highest potency, reducing volumes by 75% compared to 5mg/mL. This suits patients preferring minimal injection volume. However, starting dose (0.125mL) approaches or exceeds practical measurement limits of standard insulin syringes. High-concentration vials require tuberculin syringes (0.01mL increments) for accuracy, which are less commonly available than insulin syringes.
Recommendation: Select 5mg/mL or 10mg/mL concentration for optimal accuracy and practical administration without specialized equipment.
Units to Milligrams Conversion Reference
Insulin syringes measure volume in units (100 units = 1mL). The following conversion table helps convert insulin syringe units to milliliters of various tirzepatide concentrations:
| Syringe Units | Milliliters (mL) | @ 5mg/mL | @ 10mg/mL | @ 20mg/mL |
|---|---|---|---|---|
| 5 units | 0.05 mL | 0.25mg | 0.5mg | 1mg |
| 10 units | 0.1 mL | 0.5mg | 1mg | 2mg |
| 25 units | 0.25 mL | 1.25mg | 2.5mg | 5mg |
| 50 units | 0.5 mL | 2.5mg | 5mg | 10mg |
| 75 units | 0.75 mL | 3.75mg | 7.5mg | 15mg |
| 100 units | 1.0 mL | 5mg | 10mg | 20mg |
Injection Volume Calculator Reference
To calculate injection volume for any dose and concentration:
Formula: Volume (mL) = Desired Dose (mg) ÷ Concentration (mg/mL)
Example 1: You need 7.5mg with 5mg/mL vial
Volume = 7.5mg ÷ 5mg/mL = 1.5mL
Example 2: You need 10mg with 10mg/mL vial
Volume = 10mg ÷ 10mg/mL = 1.0mL
Example 3: You need 2.5mg with 20mg/mL vial
Volume = 2.5mg ÷ 20mg/mL = 0.125mL (very small, requires tuberculin syringe)
Create a reference chart specific to your concentration and print it for easy reference during injections.
Storage and Handling of Compounded Tirzepatide
Proper storage maintains potency and prevents degradation:
Before First Use: Store at 2-8°C (refrigerator temperature, 36-46°F). Keep in original packaging away from light. Do not freeze. Frozen tirzepatide loses potency.
After Opening/First Use: Continue refrigerating at 2-8°C. Typical shelf life is 30-60 days after opening, though this varies by compounding pharmacy and carrier solution. Check label for specific expiration date.
During Administration: Allow vial to reach room temperature (5-10 minutes) before withdrawing dose to ensure consistent concentration and reduce discomfort. Inject at room-temperature medication, not cold.
Important: Ask your compounding pharmacy for specific storage instructions, shelf-life after opening, and expiration dates for your particular vial. Storage requirements vary by compounding pharmacy and carrier solutions used.
Injection Technique and Best Practices
Safe, effective tirzepatide injection requires proper technique:
Supplies Needed: Insulin syringe (appropriate size for your concentration), injection needle (typically 28-30 gauge, 0.5-inch length), alcohol pad or chlorhexidine swab, sterile gauze.
Injection Sites: Abdomen (preferred, most consistent absorption), upper thigh, or upper arm. Rotate injection sites to prevent lipodystrophy (tissue damage from repeated injections in same location). Avoid areas with scars, bruising, or existing tissue damage.
Injection Steps:
- Wash hands thoroughly with soap and water
- Inspect vial for particles or discoloration; do not use if cloudy
- Wipe injection site with alcohol pad; allow to dry (important: alcohol kills bacteria)
- Draw calculated dose into syringe
- Pinch skin at injection site between thumb and fingers
- Insert needle at 45-90 degree angle
- Inject medication by slowly pushing plunger
- Withdraw needle and apply pressure with sterile gauze
- Cover injection site with bandage if needed
Important: Subcutaneous injection (under skin, not into muscle) is correct for tirzepatide. Incorrect injection technique or intradermal injection (too shallow) reduces absorption.
Comparing Compounded Tirzepatide to Brand Mounjaro/Zepbound
While tirzepatide molecule is identical between compounded and brand formulations, important differences exist:
| Factor | Compounded Tirzepatide | Brand Mounjaro/Zepbound |
|---|---|---|
| Tirzepatide Molecule | Identical | Identical |
| Delivery Format | Multi-dose vial, manual injection | Pre-filled pen with auto-injector |
| Cost | $300-500/month | $1,300-1,600/month |
| FDA Approval | Finished product not FDA-approved | FDA-approved |
| Quality Assurance | State pharmacy board regulated | FDA regulated manufacturing |
| Potency Consistency | Variable (depends on pharmacy) | Guaranteed consistent potency |
| Convenience | Requires measurement and injection | Pre-measured, easy injection |
Related Guides
Frequently Asked Questions
The FDA-approved tirzepatide titration schedule is: Week 1-4: 2.5mg once weekly. Week 5-8: 5mg once weekly. Week 9-12: 7.5mg once weekly. Week 13-16: 10mg once weekly. Week 17-20: 12.5mg once weekly. Week 21+: 15mg once weekly. This 6-step titration occurs over approximately 20+ weeks, allowing gradual dose escalation to minimize gastrointestinal side effects (nausea, vomiting, constipation). Each dose is administered as a subcutaneous injection once weekly on the same day. Some patients achieve adequate results before reaching 15mg and remain on lower maintenance doses permanently.
Three primary concentrations are standard: 5mg/mL (most common, practical for all doses), 10mg/mL (moderate concentration for medium doses), and 20mg/mL (highest concentration). The 5mg/mL concentration is most practical for titration schedules because dose volumes remain measurable throughout progression. Higher concentrations (10mg/mL, 20mg/mL) may require very small volumes at starting doses, making accurate measurement challenging with standard insulin syringes. Lower concentrations (5mg/mL) produce larger volumes that are more easily measured and drawn with standard syringes.
Use the formula: Volume = Dose ÷ Concentration. For 2.5mg dose with 5mg/mL: 2.5mg ÷ 5mg/mL = 0.5mL. With 10mg/mL: 0.25mL. With 20mg/mL: 0.125mL. For 15mg dose with 5mg/mL: 3mL. With 10mg/mL: 1.5mL. With 20mg/mL: 0.75mL. Lower concentrations produce larger volumes; higher concentrations produce smaller volumes. For accuracy, select 5mg/mL or 10mg/mL concentration to ensure all doses produce measurable injection volumes (0.25mL minimum).
Standard insulin syringes measure in 1-unit increments (100 units = 1mL), providing accuracy to approximately 0.01mL or 0.1mg tirzepatide. For most doses, this is adequate. Starting doses (2.5-5mg) from high-concentration vials (20mg/mL) may require volumes of 0.125-0.25mL, approaching syringe accuracy limits. For optimal accuracy, choose 5mg/mL or 10mg/mL concentrations producing measurable volumes throughout titration. If using 20mg/mL vials, request tuberculin syringes (marked in 0.01mL increments) from your pharmacy for improved accuracy.
Compounded tirzepatide storage requirements vary but are typically: Refrigerate at 2-8°C (36-46°F) until first use. After opening, store refrigerated at 2-8°C. Typical shelf life is 30-60 days after opening, though this varies by compounding pharmacy and carrier solution. Keep vials in original packaging away from light. Do not freeze. Do not use if frozen. Check expiration dates on vial. Ask your compounding pharmacy for specific storage instructions and shelf-life duration for your vial concentration and carrier solution. Store away from children and pets.
Essential supplies: insulin syringes (appropriate size for your vial concentration), injection needles (typically 28-30 gauge, 0.5-inch length), alcohol pads or chlorhexidine for site cleaning, bandages for injection sites. Optional supplies: glucagon emergency kit (if diabetic), sharps disposal container for safe needle disposal, insulin pen to practice technique. Your compounding pharmacy may provide some supplies; verify what's included. Standard diabetic supply retailers sell syringes, needles, and alcohol pads. Sharps containers are available from pharmacies or medical supply stores.
Lyophilized (freeze-dried) tirzepatide powder is less common in compounded preparations but may be used in some pharmacies. Reconstitution involves: (1) Remove vial from refrigeration and allow to reach room temperature (5-15 minutes). (2) Use sterile needle and syringe to draw specified volume of bacteriostatic water or carrier solution. (3) Slowly inject into lyophilized powder vial at angle (not directly on powder). (4) Gently rotate vial to mix; do not shake vigorously. (5) Allow 2-5 minutes for complete dissolution. (6) Solution should be clear before use. If cloudy or particles present, do not use. Most patients receive pre-compounded solutions (already mixed), not lyophilized powder requiring reconstitution. Confirm with pharmacy which form you receive.
Yes, switching between compounded tirzepatide and brand Mounjaro/Zepbound pens is straightforward because they contain identical tirzepatide molecules. Pharmacologic effects (weight loss, glucose control, side effects) are identical at equal doses. Practical differences: Mounjaro/Zepbound pens are convenient and pre-measured; compounded requires manual measurement. Mounjaro/Zepbound are FDA-approved; compounded lacks finished-product approval. Mounjaro/Zepbound cost $1,300-1,600/month; compounded costs $300-500/month. You can switch between them at any time. If on compounded at 7.5mg, switching to brand Mounjaro 7.5mg pen is seamless—dosing is equivalent. Some patients alternate (compounded when cash-strapped, brand when affordable).
If you miss a weekly injection: (1) If less than 2 days late, inject as soon as possible and maintain weekly schedule from that day. (2) If 2-4 days late, inject as soon as possible. Your next injection occurs 7 days from this injection. (3) If more than 4 days late, contact your prescriber for guidance. Do not attempt to make up missed doses by doubling next dose—this risks increased side effects. Maintain consistent weekly schedule. If frequently missing doses, set phone reminders or calendar alerts for injection day. Most patients choose same day each week (e.g., every Monday) to simplify adherence.